Premium
Injectable naltrexone found as effective as buprenorphine in noninferiority trial
Publication year - 2018
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30292
Subject(s) - naltrexone , buprenorphine , medicine , opioid , (+) naloxone , narcotic antagonists , anesthesia , pharmacology , receptor
A 12‐week trial conducted in Norway has found injectable extended‐release naltrexone to be noninferior to oral buprenorphine‐naloxone on a number of outcomes for opioid‐dependent patients, including treatment retention and opioid‐negative drug tests. These results have significant implications because the study represents one of the first direct comparisons between injectable naltrexone and what has become the standard‐of‐care treatment for opioid dependence in several countries. Study results were published online Oct. 18 in JAMA Psychiatry .